To the Editor.—
Previous studies have established that methoxsalen (PUVA [methoxsalen plus ultraviolet light]) is an effective mode of treatment for psoriasis.1 In a recent article in The Journal, Stern et al (1981;245:1913) have demonstrated that this outpatient procedure is cost-effective for the treatment of psoriasis in view of the need for hospitalization for many such patients. This view was supported in an editorial by Henry H. Roenigk, MD, in the same issue (1981; 245:1941), who advocated Food and Drug Administration approval of labeling to recommend this procedure.However, the authors did not include in their equations the expenditures related to an already established risk of the treatment. Stern et al have demonstrated a significant increase in the skin cancer formation induced by this modality during a four-year period.2,3 These cancers will require biopsies, histological examinations, and definitive therapy (eg, surgery, ionizing radiation) for complete eradication. The costs
Farber EM, Abel EA, Epstein JH, Cram DA. Cost-effectiveness of PUVA Therapy: Further Considerations. JAMA. 1982;247(13):1808. doi:10.1001/jama.1982.03320380014008
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: